Kidney-type glutaminase (GLS1) is a biomarker for pathologic diagnosis and prognosis of hepatocellular carcinoma
about
A novel glutaminase inhibitor-968 inhibits the migration and proliferation of non-small cell lung cancer cells by targeting EGFR/ERK signaling pathway.Development and Validation of a Three-gene Prognostic Signature for Patients with Hepatocellular CarcinomaThe Glutaminase-1 Inhibitor 968 Enhances Dihydroartemisinin-Mediated Antitumor Efficacy in Hepatocellular Carcinoma CellsDrug-induced amino acid deprivation as strategy for cancer therapy.Blockage of glutaminolysis enhances the sensitivity of ovarian cancer cells to PI3K/mTOR inhibition involvement of STAT3 signaling.An update on the use of benzoate, phenylacetate and phenylbutyrate ammonia scavengers for interrogating and modifying liver nitrogen metabolism and its implications in urea cycle disorders and liver disease.Tumor repressor gene chondroadherin oppose migration and proliferation in hepatocellular carcinoma and predicts a good survival.Role of the Transforming Growth Factor-β in regulating hepatocellular carcinoma oxidative metabolism.Hedgehog-YAP Signaling Pathway Regulates Glutaminolysis to Control Hepatic Stellate Cell Activation.Glutaminolysis is required for TGF-β1-induced myofibroblast differentiation and activation.Glutamine Metabolism in Gliomas.Targeting Glutamine Metabolism for Cancer Treatment.Hepatitis C virus core impacts expression of miR122 and miR204 involved in carcinogenic progression via regulation of TGFBRAP1 and HOTTIP expression.Nuclear factor-κB p65 regulates glutaminase 1 expression in human hepatocellular carcinoma.
P2860
Q33709577-4F4C0889-96B8-47E4-86F6-441AA4F3598CQ33911829-8BBBD58C-63C0-4F19-8062-A8DBD621F1D7Q36189879-ABEB3D8C-3462-4D99-A395-12D3F40824B4Q38657061-6F072E76-79EC-4633-A5E7-D44427CB5F08Q38792699-AE6C92DB-E31B-46E4-9A07-C3711BBAAD0CQ39012545-206ED69C-A4D4-4D41-AEF9-9F9ABE2A93FBQ41694075-32EC72A4-CFB7-4309-940A-A8FBDEC6DD93Q42108995-BC90670C-E0D7-4437-800F-7F943E671494Q47227996-A3C28002-E2E1-4002-9274-B50A91516836Q47313541-7B0CDA66-22C8-4A6C-9EB9-E1D4C3EEA798Q48417468-0A4787FB-F01B-4A1A-AC65-4CFF719D992FQ49632469-21902FC5-D548-49D2-B7D9-453B175A4627Q53177200-09F5F73B-C524-408C-B442-49A1CFC29B83Q55497559-8EEDEFA2-FE2F-49F3-833B-DE044A161867
P2860
Kidney-type glutaminase (GLS1) is a biomarker for pathologic diagnosis and prognosis of hepatocellular carcinoma
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Kidney-type glutaminase (GLS1) ...... is of hepatocellular carcinoma
@ast
Kidney-type glutaminase (GLS1) ...... is of hepatocellular carcinoma
@en
type
label
Kidney-type glutaminase (GLS1) ...... is of hepatocellular carcinoma
@ast
Kidney-type glutaminase (GLS1) ...... is of hepatocellular carcinoma
@en
prefLabel
Kidney-type glutaminase (GLS1) ...... is of hepatocellular carcinoma
@ast
Kidney-type glutaminase (GLS1) ...... is of hepatocellular carcinoma
@en
P2093
P2860
P356
P1433
P1476
Kidney-type glutaminase (GLS1) ...... is of hepatocellular carcinoma
@en
P2093
Xianbiao Shi
Yitao Ding
Yong Jiang
P2860
P304
P356
10.18632/ONCOTARGET.3196
P407
P577
2015-04-01T00:00:00Z